A mouse-based strategy for cyclophosphamide pharmacogenomic discovery

Journal of Applied Physiology

Volumn 95, Issue 4, 2003, Pages 1352-1360

  Watters, James W ^a   Kloss, Ellen F ^a   Link, Daniel C ^a,b   Graubert, Timothy A ^a,b   McLeod, Howard L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Mobilization; Pharmacogenetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE MAPPING; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEMATOPOIETIC STEM CELL; HYBRID; IN VITRO STUDY; MALE; MOUSE STRAIN; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0141451862     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00214.2003     Document Type: Article

References (35)

1. Bishop CE, Boursot P, Baron B, Bonhomme F, and Hatat D. Most classical Mus musculus domesticus laboratory mouse strains carry a Mus musculus musculus Y chromosome. Nature 315: 70-72, 1985.
2. Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 5: 555-560, 1999.
3. Dragani TA, Zunino A, and Sozzi G. Differences in sister chromatid exchange (SCE)-induction in vivo by cyclophosphamide in murine strains. Carcinogenesis 2: 219-222, 1981.
4. Evans WE and Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genom Human Genet 2: 9-39, 2001.
5. Evans WE and McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003.
6. Evans WE and Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999.
7. Hasegawa M, Baldwin TM, Metcalf D, and Foote SJ. Progenitor cell mobilization by granulocyte colony-stimulating factor controlled by loci on chromosomes 2 and 11. Blood 95: 1872-1874, 2000.
8. Huang Z, Roy P, and Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59: 961-972, 2000.
9. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, and Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111: 187-196, 2003.
10. Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, and LeCluyse EL. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 30: 814-822, 2002.
11. Link DC. Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. Semin Hematol 37: 25-32, 2000.
12. Liu F, Poursine-Laurent J, and Link DC. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood 90: 2522-2528, 1997.
13. Miller RD, Duan S, Lovins EG, Kloss EF, and Kwok PY. Efficient high-throughput resequencing of genomic DNA. Genome Res 13: 717-720, 2003.
14. Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, and Keating MJ. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97: 114-120, 2003.
15. Morrison SJ, Wright DE, and Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA 94: 1908-1913, 1997.
16. Neben S, Marcus K, and Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 81: 1960-1967, 1993.
17. Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 410: 107-120, 2000.
18. Parchment RE, Huang M, and Erickson-Miller CL. Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21: 241-250, 1993.
19. Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, Croera C, Parchment R, Parent-Massin D, Schoeters G, Sibiri Y, Van Den Heuvel R, and Gribaldo L. In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay. Altern Lab Anim 30: 75-79, 2002.
20. Pessina A, Albella B, Bueren J, Brantom P, Casati S, Gribaldo L, Croera C, Gagliardi G, Foti P, Parchment R, Parent-Massin D, Sibiril Y, and Van Den Heuvel R. Pre-validation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 15: 729-740, 2001.
21. Pevnitsky LA, Telegin L, Zhirnov GF, Mazurov AV, and Viktorov VV. Sensitivity to immunodepressant action of cyclophosphamide: analysis of interstrain differences in mice. Int J Immunopharmacol 7: 875-880, 1985.
22. Phillips K, Veenstra D, Oren E, Lee J, and Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 286: 2270-2279, 2001.
23. Reimer DL and Singh SM. Cyclophosphamide-induced in vivo sister chromatid exchanges (SCE) in Mus musculus. III. Quantitative genetic analysis. Genetics 105: 169-179, 1983.
24. Risch N and Merikangas K. The future of genetic studies of complex human diseases. Science 273: 1516-1517, 1996.
25. Roberts AW, Foote S, Alexander WS, Scott C, Robb L, and Metcalf D. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 89: 2736-2744, 1997.
26. Rozen S and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386, 2000.
27. Semerad CL, Liu F, Gregory AD, Stumpf K, and Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 17: 413-423, 2002.
28. Silver LM. Mouse Genetics. New York: Oxford Univ. Press, 1995.
29. Telegin L, Zhirnov GF, Mazurov AV, and Pevnitskii LA. Immunosuppressant effect of cyclophosphamide activated in vitro by liver microsomes from different strains of mice. Biull Eksp Biol Med 92: 57-60, 1981.
30. To L, Haylock D, Simmons P, and Juttner C. The biology and clinical uses of blood stem cells. Blood 89: 2233-2258, 1997.
31. Vieux EF, Kwok PY, and Miller RD. Primer design for PCR and sequencing in high-throughput analysis of SNPs. Biotechniques Suppl: 28-30, 32, 2002.
32. Wade CM, Kulbokas EJ, Kirby AW III, Zody MC, Mullikin JC, Lander ES, Lindblad-Toh K, and Daly MJ. The mosaic structure of variation in the laboratory mouse genome. Nature 420: 574-578, 2002.
33. Watters JW and McLeod HL. Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics 3: 781-790, 2002.
34. Watters JW and McLeod HL. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol Sci 24: 55-58, 2003.
35. Xie HJ, Lundgren S, Broberg U, Finnstrom N, Rane A, and Hassan M. Effect of cyclophosphamide on gene expression of cytochromes p450 and β-actin in the HL-60 cell line. Eur J Pharmacol 449: 197-205, 2002.